目的 探讨苏黄止咳胶囊联合氨溴索治疗慢性阻塞性肺疾病急性加重期的临床效果。方法 选取2015年6月—2018年6月天津市泰达医院收治的160例慢性阻塞性肺疾病急性加重期患者，随机分成对照组和治疗组，每组各80例。对照组静脉滴注盐酸氨溴索注射液，30 mg加入5%葡萄糖溶液100 mL中充分稀释，而后慢速静脉输注，2次/d。治疗组在对照组基础上口服苏黄止咳胶囊，3粒/次，3次/d。两组均连续治疗10 d。观察两组的临床疗效，比较两组症状缓解时间、肺功能指标、血清学指标和CAT评分的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是87.50%、96.25%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组气短、咳嗽、咳痰、肺部哮鸣音等主要症状的缓解时间均显著短于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组第1秒用力呼气容积（FEV1）与用力肺活量（FVC）比值（FEV1/FVC）、FEV1占预计值百分比（FEV1% pred）、每分钟最大通气量占预计值百分比（MVV% pred）均较治疗前显著上升，而残气容积（RV）与肺总量（TLC）比值（RV/TLC）均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组FEV1/FVC、FEV1% pred、MVV% pred均高于对照组，而RV/TLC低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清肿瘤坏死因子-α（TNF-α）、8-羟基脱氧鸟苷（8-OHdG）、C反应蛋白（CRP）和慢性阻塞性肺疾病患者自我评估测试（CAT）评分均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组TNF-α、8-OhdG、CRP和CAT评分低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 苏黄止咳胶囊联合氨溴索治疗慢性阻塞性肺疾病急性加重期具有较好的临床疗效，可迅速缓解患者症状，保护肺功能，抑制机体炎症反应，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Suhuang Zhike Capsules combined with ambroxol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (160 cases) with acute exacerbation of chronic obstructive pulmonary disease in Tianjin TEDA Hospital from June 2015 to June 2018 were randomlydivided into control (80 cases) and treatment (80 cases) groups. Patients in the control group were iv administered with Ambroxol Hydrochloride Injection, 30 mg was added to 5% glucose solution100 mL, which was fully diluted, and then slowly intravenous infusion, twice daily. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical efficacy was evaluated, and symptom relief time, lung function indexes, serological indexes and CAT scores in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 87.50% and 96.25%, respectively, and there were differences between two groups (P<0.05). The remission time of main symptoms such as shortness of breath, cough, expectoration and lung asthma in the treatment group was significantly shorter than that in the control group, and there were differences between two groups (P<0.05). After treatment, FEV1/FVC, FEV1%pred, and MVV%pred in two groups were significantly increased, but RV/TLC was significantly decreased, and there were differences in the same group (P<0.05). After treatment, FEV1/FVC, FEV1%pred, and MVV%pred in the treatment group were higher than those in the control group, but RV/TLC was lower than that in the control group, and there were differences between two groups (P<0.05). After treatment, TNF-α, 8-OhdG, CRP, and CAT scores were significantly decreased, and there were differences in the same group (P<0.05). After treatment, TNF-α, 8-OhdG, CRP, and CAT scores in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Suhuang Zhike Capsules combined with ambroxol has significant effect in treatment of acute exacerbation of chronic obstructive pulmonary disease, and can rapidly relieve symptoms, and also can protect lung function, and inhibit the body's inflammatory response, which has a certain clinical application value.